血浆多蛋白组合提升新皮层tau负荷识别
本研究基于瑞典BioFINDER与TRIAD两个独立观察队列共560例淀粉样蛋白阳性个体,开发并验证了一个7蛋白血浆组合,用于识别Braak V–VI期tau PET摄取。该组合较单用p-tau217显著提高识别性能,并减少中间风险分类比例,提示多蛋白策略可能成为tau PET分期的可扩展替代方案。
要点
- 在淀粉样蛋白阳性人群中,7蛋白血浆组合识别Braak V–VI期tau PET摄取优于单用p-tau217。
- 该组合在发现与验证队列中AUC为0.92–0.94,较p-tau217的0.86–0.88显著提升。
- 验证队列中中间风险区间个体比例因此减少14.7%至21.0%。
核心结论
- 在淀粉样蛋白阳性个体中,加入额外血浆蛋白可显著提升p-tau217对晚期tau病理的预测性能。
- 多蛋白血浆panel可能为临床或研究场景提供可扩展的tau PET分期替代方案。
研究设计与样本
- 多中心队列研究,纳入瑞典BioFINDER与TRIAD两个独立观察队列,横断面临床数据与血样采集于2017至2024年。
- 共560例淀粉样蛋白阳性参与者,涵盖从认知未受损到痴呆的临床谱系;BioFINDER n=431,TRIAD n=129。
- 采用Nucleic Linked Immuno-Sandwich Assay中枢神经系统panel检测125种血浆蛋白浓度。
主要发现
- 以Braak V–VI期区域tau PET摄取定义晚期tau病理,多变量逻辑回归在BioFINDER中发现7蛋白组合。
- 该7蛋白组合识别晚期tau病理的AUC为0.92–0.94(95%CI 0.89–0.98),优于p-tau217的AUC 0.86–0.88(95%CI 0.82–0.94),DeLong P < .001。
- 验证队列中,该组合使中间风险范围(配对敏感度与特异度阈值之间)个体比例减少14.7%至21.0%。
关键数值与推荐
- 晚期tau病理定义为tau PET摄取位于Braak V和VI期区域。
- 预测性能以受试者工作特征曲线下面积(AUC)评价。
- 7蛋白组合较p-tau217的AUC提升在发现与验证队列中均具统计学意义(DeLong P < .001)。
临床怎么用
- 对于淀粉样蛋白阳性个体,可考虑多蛋白血浆panel辅助识别新皮层tau负荷,以优化患者分层与临床试验入选。
- 该策略有望在临床或研究中减少对tau PET分期的依赖,但需进一步外部验证后方可用于常规决策。
局限性
- 研究为横断面设计,无法评估血浆蛋白组合对tau病理进展的纵向预测价值。
- 样本仅纳入淀粉样蛋白阳性个体,结论不能外推至淀粉样蛋白阴性人群。
- 研究基于两个观察队列,外推至其他人群或检测平台时需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Phosphorylated tau-217 (p-tau217) is now an established plasma biomarker for assessing amyloid-β pathology in individuals at risk of Alzheimer disease. However, its performance in identifying advanced neocortical neurofibrillary tangle burden remains suboptimal. Precise assessment of tau pathology is increasingly critical for the rational implementation of anti-amyloid therapies and developing anti-tau interventions. Improved biofluid biomarker-based tau staging could enhance patient stratification and optimize participant selection for clinical care and therapeutic trials. OBJECTIVE: To develop and validate a multiprotein plasma panel to improve identification of neocortical tau pathology beyond p-tau217 alone. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study included 2 independent observational cohorts, Swedish BioFINDER study and Translational Biomarkers in Aging and Dementia (TRIAD). Cross-sectional clinical data and blood samples were collected between 2017 and 2024. Participants included 560 individuals spanning the clinical spectrum from cognitively unimpaired to dementia. These data were analyzed from January 2025 to May 2026. EXPOSURES: Plasma concentrations of 125 proteins measured using Nucleic Linked Immuno-Sandwich Assay central nervous system panel. MAIN OUTCOME AND MEASURE: Advanced tau pathology defined as tau positron emission tomography (PET) uptake within Braak stage V and VI regions. Predictive performance of biomarker models was evaluated using area under the receiver operating characteristic curve (AUC). RESULTS: The study included 560 amyloid-positive participants (BioFINDER: n = 431; mean [SD] age, 73.6 [7.0] years; 212 female [49.2%] and 219 male [50.8%]; TRIAD: n = 129; mean [SD] age, 70.4 [8.3] years; 76 female [58.9%] and 53 male [41.1%]). Using multivariable logistic regression approaches, a 7-protein panel was found in BioFINDER to identify tau PET uptake within Braak stage V and VI regions. When compared with p-tau217 (AUC, 0.86-0.88; 95% CI, 0.82-0.94), this multiprotein panel was associated with improved identification in both discovery and validation cohorts (AUC, 0.92-0.94; 95% CI, 0.89-0.98; DeLong P < .001). This reduced the proportion of individuals classified within the intermediate-risk range (between paired sensitivity and specificity thresholds) in the validation cohort by 14.7% to 21.0%. CONCLUSIONS AND RELEVANCE: This multicohort study demonstrated how including additional plasma proteins significantly enhanced the performance of p-tau217 in predicting advanced tau pathology among amyloid-positive individuals. This suggests a multiprotein approach may offer a viable and scalable alternative to tau PET staging in clinical or research settings.
引用
- Di Molfetta G, Brum WS, Pola I, et al. Plasma Biomarkers for Neocortical Tau Burden. JAMA Neurol. 2026. PMID: 42573994. doi:10.1001/jamaneurol.2026.2650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。